RADNOR, Pa., Nov. 26, 2014 /PRNewswire/ -- Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the company will present at the Piper Jaffray 26th Annual Healthcare Conference 2014. The conference will be held December 2 to 3, 2014,at the New York Palace in New York. Zynerba's Chairman and CEO, Armando Anido, will present at 4:50 pm on Tuesday, December 2.
To listen to a webcast of this presentation during the event, please visit the Investor Relations page of www.zynerba.com.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals is dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs using modern drug delivery technology and appropriate regulatory pathways. Zynerba is developing two therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of cannabinoids. Transdermal delivery reduces adverse effects associated with oral dosing. ZYN001 will be studied in chronic cancer pain, fibromyalgia, and peripheral neuropathic pain utilizing a synthetically manufactured prodrug of THC in a transdermal patch to deliver THC through the skin and into the bloodstream. Zynerba expects to initiate ZYN001 Phase 1 clinical studies in 3Q 2015. ZYN002 will be studied in refractory epilepsy and arthritis, utilizing a proprietary gel to deliver synthetically manufactured cannabidiol (CBD), a non-psychotropic cannabinoid, through the skin and into the bloodstream. Zynerba expects to initiate ZYN002 Phase 1 clinical studies in 3Q 2015. Learn more at www.zynerba.com and follow the company on Twitter at @ZynerbaPharma.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zynerba-pharmaceuticals-to-present-at-piper-jaffray-26th-annual-healthcare-conference-2014-300001456.html
SOURCE Zynerba Pharmaceuticals, Inc.
